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ABSTRACT
The goal of this study was to synthesize and evaluate a novel bombesin (BN) analogue containing a poly-
ethylene glycol (PEG) linker that can be radiolabeled with 64Cu through the DOTA bifunctional chelate.
It is hypothesized that PEG linkers would improve the pharmacokinetics of radiolabeled bombesin ana-
logues to optimize their tumor-to-normal tissue ratios for radiotherapy applications. The formation of this
conjugate (DOTA-PEG-BN(7-14)) was confirmed by MALDI-TOF mass spectrometry and was radiola-
beled with 64Cu at a specific activity of 2.7 MBq/nmol. DOTA-PEG-BN(7-14) bound specifically to gas-
trin-releasing peptide receptor (GRPR)-positive PC-3 cells with an IC50 value of 3.9 mM for displacing
125I-Tyr4-BN. Internalization of 64Cu-DOTA-PEG-BN(7-14) into PC-3 cells showed that 5.7%, 13.4%,
and 21.0% was internalized at 0.5, 2, and 4 hours, respectively. Biodistribution of 64Cu-DOTA-PEG-
BN(7-14) was evaluated in normal, athymic nude mice 2, 4, and 24 hours after i.v. injection. This showed
that most of the tissues had a similar uptake and clearance of 64Cu-DOTA-PEG-BN(7–14) compared to
a control peptide with an alkyl linker (DOTA-Aoc-BN(7-14)) at the given time points. There was uptake
of 10.8% ID/g of 64Cu-DOTA-PEG-BN(7-14) 4 hours after i.v. injection in the GRPR-positive pancreas
that was inhibited to 2.4% upon injection of an excess of Tyr4-BN. These studies demonstrate that BN
analogues can be conjugated with PEG linkers, radiolabeled with 64Cu, and bind to GRPR. Future stud-
ies will attempt to increase the affinity of these analogues for GRPR and alter the pharmacokinetics of
the 64Cu-labeled conjugates through the use of various sized PEG linkers.
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INTRODUCTION
Radioimmunotherapy is a well-established mo-
dality for the treatment of cancer through the spe-
cific delivery of radiation. In general, radioactiv-
ity has been delivered to the tumor site by 
attaching it to a monoclonal antibody that is se-
lective for the tumor tissue. One drawback to this
approach is that only a limited amount of ra-
dioactivity can be delivered to the tumor due to
the bone marrow toxicity that is caused by ad-
ministration of therapeutic doses of the radiola-
beled antibody.1 This toxicity is due to the long
serum half-life of antibodies that results in a high
radiation dose delivered to bone marrow.2 To ad-
dress this limitation, peptides have been used to
deliver radiation to the tumor site in place of an-
tibodies. Radiolabeled peptides have the advan-
tage of clearing the serum more rapidly than 
antibodies, thus lowering the radiation dose de-
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livered to the bone marrow. In particular, oc-
treotide analogues radiolabeled with indium-111
and yttrium-90 have been evaluated clinically for
the treatment of somatostatin receptor subtype 2-
positive tumors.3,4
One limiting factor in the use of radiolabeled
peptides for cancer therapy is that the rapid serum
clearance of the peptide can lead to a lower radia-
tion dose delivered to the tumor. Because the pep-
tide clears from serum rapidly, there is little time
for the peptide to build a high concentration in the
tumor. Thus, the best vehicle for delivery of ther-
apeutic radioisotopes would balance the tumor up-
take with the serum clearance. In this regard, sev-
eral studies have used chemical conjugates or
genetic engineering to alter the pharmacokinetics
of tumor targeting ligands. Monoclonal antibodies,
single-chain Fv proteins (scFv), and chemothera-
peutic drugs have been chemically conjugated with
dextran, polyethylene glycol (PEG), poly(L-lysine),
or N-(2-hydroxypropyl)methacrylamide copoly-
mer (HMPA) as scaffolds to form the chemical
links to alter their pharmacokinetics.5–10 Geneti-
cally engineered antibodies that have improved
pharmacokinetics compared to intact antibodies,
antibody fragments, or scFvs have recently been
studied.11,12
We hypothesized that the chemical conjugation
of a peptide to a PEG scaffold would improve the
pharmacokinetics of the resulting conjugate for
delivery of radioisotopes to a tumor site. As a
model system, we used the eight C-terminal
amino acids of the amphibian tetradecapeptide
bombesin (BN), which binds with high affinity
to the gastrin-releasing peptide receptor (GRPR)
overexpressed on a variety of human carcino-
mas.13–17 BN analogues have been evaluated as
therapeutic and diagnostic agents in clinical and
pre-clinical studies after labeling with a variety of
radioactive metals.18–30 In the present study, we
conjugated the N-terminus of BN(7-14) to a 3,500
Da PEG derivative and coupled the resulting con-
jugate (PEG-BN(7-14)) to 1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetic acid (DOTA) via
the N-terminus of the PEG moiety for radiolabel-
ing with 64Cu. The 64Cu-DOTA-PEG-BN(7-14)
was evaluated and compared to a control peptide
(64Cu-DOTA-Aoc-BN(7-14)) containing an eight
carbon spacer in place of PEG in vitro using GRPR-
expressing PC-3 human prostate cancer cells and
in vivo in normal athymic nude mice. The 64Cu-
DOTA-Aoc-BN(7-14) was recently evaluated in
mice bearing PC-3 tumor xenografts and shown to
be useful for microPET imaging.30 The structures
of DOTA-PEG-BN(7-14) and DOTA-Aoc-BN(7-
14) are shown in Figure 1.
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Figure 1. Structures and amino acid sequence of DOTA-Aoc-BN(7-14) (A) and DOTA-PEG-BN(7-14) (B). The average mo-





acid-t-butyl ester)-10-acetic acid (DOTA-tris
(t-butyl ester)) was purchased from Macro-
cyclics, Inc. (Dallas, TX) and 8-amino-octanoic
(Aoc) acid was purchased from Advanced
ChemTech (Louisville, KY). The DOTA-Aoc-
BN(7-14) was synthesized using standard Fmoc
chemistry by solid phase peptide synthesis using
a Rink amide resin at the University of Alabama
at Birmingham Comprehensive Cancer Center
Peptide Synthesis and Analysis Shared Facility
and shown to be. 98% pure by high perfor-
mance liquid chromatography (HPLC).
The PEG-BN(7-14) was synthesized in a man-
ner similar to that described before.8 Briefly, the
BN(7-14) (3 mg, 2.8 mmol), also synthesized at the
UAB Peptide Synthesis and Analysis Shared Fa-
cility, was dissolved in 200 mL of dry DMF and 5
mL of diisopropyl ethylamine (DIEA) were added
with stirring. This solution was then added to N-
hydroxysuccinimidyl Na-Fmoc-PEG-carboxylate
(9.9 mg, 2.9 mmol) (Nektar Therapeutics, Hunts-
ville, AL) in 100 mL of the same solvent and the
reaction mixture was stirred at 4°C for 2 hours.
Piperidine (200 mL) was added at 0°C and the
solution was stirred at this temperature for 10
minutes after which time the liquids were re-
moved under high vacuum and the H2N-PEG-
BN(7-14) residue was purified by semi-prepara-
tive reversed-phase HPLC.
To a solution of DOTA-tris(t-butyl ester) (1.53
mg, 2.7 mmol) in 150 mL of DMF, was added
DIEA (0.5 mL) followed by O-benzotriazol-1-
yl-N, N, N9, N9-tetramethyluronium hexafluo-
rophosphate (0.97 mg, 2.7 mmol). After 20 min-
utes, a solution of H2N-PEG-BN(7-14) in 200 mL
of the solvent was added and the mixture was
stirred at room temperature for 2 hours. The re-
action progress was monitored by analytical
HPLC. The final product DOTA-PEG-BN(7-14)
was purified by semi-preparative HPLC and iden-
tified by matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectroscopy (MALDI-
TOF MS).
Analytical and semi-preparative HPLC used
Vydac C18 reversed-phase 4.63 10 cm and
103 250 cm columns, respectively. A linear 
gradient of 10% to 100% B in the base solvent 
A over 30 minutes was used, where A 5 wa-
ter/0.1% trifluoroacetic acid and B 5 acetoni-
trile/0.1% trifluoroacetic acid. Flow rates of 1.0
mL/minute and 2.0 mL/minute were used for the
analytical and for semi-preparative samples, re-
spectively. A BioRad model 2800 solvent deliv-
ery system, a Bio-Rad model 1806 UV/VIS de-
tector, and a Beckman model 170 radiodetector
were used for all HPLC experiments.
Radiolabeling
Copper-64 was produced on a CS-15 biomedical
cyclotron at Washington University in St. Louis
School of Medicine, according to a published
procedure.31 64CuCl2 (500 mCi) was diluted with
a 10-fold excess 0.1 M ammonium acetate
(NH4OAc), pH 5.5 and then added to DOTA-
Aoc-BN(7-14) (4 mg) or DOTA-PEG-BN(7-14)
(33 mg) in the presence of 2, 5-dihydroxybenzoic
acid (4 mg/mL final concentration) (Sigma
Chemical Co., St. Louis, MO) to prevent radioly-
sis. The reaction mixtures were incubated at room
temperature for 30 minutes and the radiochemical
purity determined by radio-thin layer chromatog-
raphy (R-TLC) or radioactivity-detecting high per-
formance liquid chromatography (R-HPLC). No
further purification was necessary for 64Cu-DOTA-
Aoc-BN(7-14), a sample of the reaction mixture
was applied to Whatman MKC18F TLC plates, de-
veloped with 10% NH4OAc:methanol (30:70,
v/v), and analyzed using a BIOSCAN System 200
imaging scanner (Washington, D.C.) to deter-
mine the purity. 64Cu-DOTA-PEG-BN(7-14) was
purified by analytical reversed-phase R-HPLC
using the gradient described above. The peak that
co-eluted with the UV peak for unlabeled DOTA-
PEG-BN(7-14) was collected, the solvent was
dried, and the residue was resuspended in PBS
with 5% EtOH prior to in vitro and in vivo use.
In vitro Competition Assay
The PC-3 human prostate cancer cell line was ob-
tained from the American Type Culture Collec-
tion (Rockville, MD) and cultured in Ham’s
F12K medium containing 10% fetal bovine serum
(FBS) and 1% L-glutamine at 37°C in a humidi-
fied atmosphere with 5% CO2. For binding assays,
the cells were harvested by incubating with 4 mM
EDTA/0.05% KCl for 3 minutes, centrifuging and
re-suspending in cold PBS at a concentration of
13 107 cells/mL. The cells (100 mL) were then
aliquoted into polystyrene tubes in triplicate fol-
lowed by the addition of 100 mL of 125I-Tyr4-BN
(0.05 nM final concentration, DuPont/NEN Re-
search Products, Boston, MA). Various amounts of
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DOTA-Aoc-BN(7-14), DOTA-PEG-BN(7-14), or
Tyr4-BN (Sigma Chemical Co.) were added in 10
mL such that the final concentrations ranged be-
tween 1 pM and 50 mM. The cells were incubated
for 1 hour at 4°C, then rinsed with PBS, and cen-
trifuged at 17003 g for 10 minutes. The super-
natant was removed, and the cells were counted in
a gamma counter (Packard Auto Gamma 5000 Se-
ries, Chicago, IL) to determine the amount of bound
radioactivity. The data were analyzed using the
GraphPad Prism software (San Diego, CA).
Internalization Assay
PC-3 cells were harvested and seeded in 6-well
plates at 3 x 105 cells per well. Twenty-four hours
later, 64Cu-DOTA-Aoc-BN(7-14) or 64Cu-DOTA-
PEG-BN(7-14) were added to the wells such that
the final concentration was 1 nM and incubated
at 37°C for 30, 120, and 240 minutes. An excess
(30 mM) of Tyr4-BN was added to half of the
wells as an inhibitor. At the appropriate time
point, a six well plate was removed from the in-
cubator, media was removed, and cells were
rinsed with PBS. The cells were then rinsed with
Hank’s Balanced Salt Solution containing 20 mM
NaOAc, pH 4.0 to remove surface-bound ra-
dioactivity and the cells were harvested by adding
1 N NaOH. The acid wash and the cells were
counted in a gamma counter to determine the
amount of surface bound and internalized ra-
dioactivity, respectively. These data were nor-
malized to the total amount of radioactivity added
to each well.
Biodistribution
Animal experiments were reviewed and approved
by the Institutional Animal Care and Use Com-
mittee at the University of Alabama at Birming-
ham. Experiments were performed in 4–5-week-
old athymic nude mice (National Cancer Institute
Frederick Research Laboratory, Frederick, MD).
The mice were injected with 185 kBq (5 mCi; 26
pmol) of 64Cu-DOTA-Aoc-BN(7-14) or 111 kBq
(3 mCi; 41 pmol) of 64Cu-DOTA-PEG-BN(7-14)
via the tail vein. Biodistribution was performed
with groups of 5 mice sacrificed 2, 4, and 24
hours post-injection of the radiolabeled ligands.
Another group of mice were co-injected with
64Cu-DOTA-Aoc-BN(7-14) (n 5 5) or 64Cu-
DOTA-PEG-BN(7–14) (n 5 3) and 100 mg of
Tyr4-BN as an inhibitor and sacrificed 4 hours
post-injection. The blood, liver, small intestine,
spleen, kidney, muscle (thigh), bone (femur), and
pancreas were removed and weighed, and the ra-
dioactivity was counted in a gamma counter to




The synthesis of the DOTA-PEG-BN(7–14)
conjugate was carried out through an active es-
ter protocol in 16% overall yield. The synthesis
was similar to that previously described for a
paclitaxel-PEG-BN(7–13) conjugate.8 The pro-
gress of the synthesis was monitored by direct
molecular weight (MW) measurements using
MALDI-TOF MS, which has proved to be a valu-
able tool for direct MW monitoring in large-mol-
ecule proteins and polymeric material.8,32 Under
the controlled reaction conditions of this synthe-
sis, the increases in MWs clearly indicated the
formation of intermediate and final-product com-
pounds, in a 1:1:1 molar ratio with respect to the
DOTA, PEG, and BN(7-14) (Fig. 2).
DOTA-Aoc-BN(7-14) was radiolabeled with
64Cu at a specific activity of 7 MBq/nmol (190
mCi/nmol) in .98% radiochemical purity as de-
termined by radio-TLC. The resulting 64Cu-
DOTA-Aoc-BN(7-14) did not require further pu-
rification and was used immediately for both in
vitro and in vivo assays. DOTA-PEG-BN(7-14)
was radiolabeled with 64Cu at a specific activity
of 2.7 MBq/nmol (73.5 mCi/nmol). The 64Cu-
DOTA-PEG-BN(7-14) was purified by HPLC
and co-eluted with the UV trace for DOTA-PEG-
BN(7-14) at 29.9 minutes. It was assumed that
the retention time of 64Cu-DOTA-PEG-BN(7-14)
would not significantly differ from the retention
time of the large, 5000 Da DOTA-PEG-BN
(7-14) and therefore, the radioactive peak corre-
sponding to the retention time of DOTA-PEG-
BN(7-14) was collected, concentrated and re-sus-
pended for in vitro and in vivo evaluation.
In vitro Evaluation
A representative competitive binding assay is
shown in Figure 3. The binding of 125I-Tyr4-BN
to PC-3 cells was inhibited by various concen-
trations of Tyr4-BN, DOTA-Aoc-BN(7-14), or
DOTA-PEG-BN(7-14). The IC50 values for Tyr4-
BN, DOTA-Aoc-BN(7-14) and DOTA-PEG-
BN(7-14) were 18.8 6 2.3 nM, 90.5 6 22.0 nM,
and 3.9 6 0.6 mM, respectively. Thus, 4.8-fold
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more DOTA-Aoc-BN(7-14) was needed than
Tyr4-BN to inhibit 125I-Tyr4-BN binding, while
DOTA-PEG-BN(7-14) required 207-fold more
than Tyr4-BN. This demonstrates that the substi-
tution of the Aoc linker with the PEG linker had
a dramatic effect on the affinity of BN(7-14) for
GRPR.
The internalization of 64Cu-DOTA-PEG-BN
(7-14) and 64Cu-DOTA-Aoc-BN(7-14) into PC-3
cells is shown in Figure 4. The amount of surface
bound radioactivity did not increase over time 
for both 64Cu-DOTA-PEG-BN(7-14) and 64Cu-
DOTA-Aoc-BN(7-14). The amount of surface
bound radioactivity for 64Cu-DOTA-Aoc-BN(7-
14) ranged from 9.3–12.4% for all time points and
was significantly greater (p, 0.0001) than the sur-
face bound radioactivity for 64Cu-DOTA-PEG-
BN(7-14) that ranged from 2.4–3.1%. When the
Tyr4-BN inhibitor was present, there was less than
0.2% of the radioactivity either surface bound or
internalized at all time points. There was a signif-
icant increase (p, 0.002) in the amount of inter-
nalized radioactivity for both compounds over the
course of the internalization assay. As with the sur-
face bound radioactivity, the amount of internal-
ized 64Cu-DOTA-Aoc-BN(7-14) was significantly
greater (p, 0.0001) than the internalization of
64Cu-DOTA-PEG-BN(7-14).
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Figure 2. MALDI-TOF spectra of unconjugated Fmoc-
PEG-NHS (A), PEG-BN(7-14) (B), and DOTA-PEG-BN(7-
14) (C). It should be noted that at a molecular level, the
polyethylene glycol (PEG) linker is a collection of mole-
cules with an average molecular weight of ,3,500 Da. The
average molecular weight of each species is shown above
the spectra. This figure demonstrates the increase in molec-
ular weight of the final DOTA-PEG-BN(7-14) relative to
the PEG starting material and PEG-BN(7-14) intermediate.
Figure 3. Inhibition of 125I-Tyr4-BN binding to PC-3 cells
with various concentrations of Tyr4-BN (triangles), DOTA-
Aoc-BN(7-14) (squares), or DOTA-PEG-BN(7-14) (cir-
cles). Results of a representative experiment are shown and
expressed as the mean cpm bound to cells6 standard devi-
ation versus the log of the concentration of ligand (n5 3).
This figure demonstrates the decrease in GRPR binding of
DOTA-PEG-BN(7-14) relative to DOTA-Aoc-BN(7-14)
and Tyr4-BN.
Figure 4. Internalization of 64Cu-DOTA-Aoc-BN(7-14)
(squares) and 64Cu-DOTA-PEG-BN(7-14) (triangles) into
PC-3 cells. At various time points after the addition of ra-
dioactivity, the cells were acid-washed to remove surface
bound radioactivity and harvested. The cell pellets (inter-
nalized, closed symbols) and acid wash (surface bound, open
symbols) were counted and the amount of internalized and
surface bound radioactivity determined. The data are pre-
sented as the mean 6 standard deviation of the % of total
radioactivity added (n5 3). Note that the error bars are con-
tained within the symbols. This figure shows that 64Cu-
DOTA-PEG-BN(7-14) is internalized although to a lesser
extent than 64Cu-DOTA-Aoc-BN(7-14).
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Figure 5. Biodistribution of 64Cu-DOTA-Aoc-BN(7-14) (squares) and 64Cu-DOTA-PEG-BN(7-14) (triangles) in normal,
athymic nude mice. The data are expressed as the % ID/g for the mean6 standard deviation of 5 mice per time point. This fig-
ure shows the comparison of the tissue uptake of 64Cu-DOTA-PEG-BN(7-14) compared to 64Cu-DOTA-Aoc-BN(7-14) at the in-
dicated time points.
In vivo Evaluation
The biodistributions of 64Cu-DOTA-PEG-BN(7-
14) and 64Cu-DOTA-Aoc-BN(7-14) at 2, 4, and
24 hours in normal, athymic nude mice are shown
in Figure 5. This shows that the only significant
differences in the uptake and retention between
64Cu-DOTA-PEG-BN(7-14) and 64Cu-DOTA-
Aoc-BN(7-14) were in the bone at 2 hours (p ,
0.03) and 24 hours (p , 0.02), the kidneys at 4
hours (p , 0.03), and the blood at 24 hours (p ,
0.04). Specific GRPR uptake for 64Cu-DOTA-
PEG-BN(7-14) and 64Cu-DOTA-Aoc-BN(7-14)
is only observed in the pancreas as shown in
Table 1. The pancreas is the only tissue that
shows a significant reduction (p , 0.005) 4 hours
after the injection of 64Cu-DOTA-PEG-BN(7-14)
or 64Cu-DOTA-Aoc-BN(7-14) upon co-injection
of an excess of Tyr4-BN.
DISCUSSION
The N-terminus of BN(7-14) was used for con-
jugation because the C-terminal amide is neces-
sary for receptor binding and the amide moiety
is not as amenable to conjugation as the amine
on the N-terminus. The overall yield of 16% for
DOTA-PEG-BN(7-14) was adequate for these
initial studies, but will need to be improved in
future studies requiring large amounts of prod-
uct. It should be noted that at a molecular level,
the PEG linker is a collection of molecules with
an average molecular weight of ,3,500 Da,
thereby the broad MALDI peaks of Figure 2.
This variation in PEG molecular weight, how-
ever, would be expected to have little effect on
in vitro binding, internalization, or in vivo phar-
macokinetics.
The in vitro binding of DOTA-PEG-BN(7-14)
to GRPR was lower than the binding of DOTA-
Aoc-BN(7-14) (Fig. 3). It is not unexpected that
the relatively large PEG moiety had an adverse
effect on the binding of BN(7-14) to GRPR. For
example, Wen et al. showed that conjugation of
PEG to a monoclonal antibody interfered with the
binding activity of the antibody.10 This example
shows that even when the PEG is small relative
to the targeting molecule (,4,000 Da PEG to
,150 kDa antibody) a negative effect on bind-
ing can occur. Of course, there were multiple
PEGs conjugated to the antibody, which also con-
tributes to the decrease in binding. To overcome
this problem, it may be necessary to develop PEG
linkers that can incorporate several BN analogues
in order to increase the valency and the affinity
of the conjugate. Lee et al. demonstrated that
PEG-sFv conjugates that contained multiple sFvs
had a higher affinity than conjugates that con-
tained a single sFv.9 Similarly, DeNardo et al.
evaluated PEG moieties that contained eight lym-
phoma specific binding peptides and demon-
strated that there was not a difference in cell bind-
ing or affinity when the size of the PEG was
increased. 33 Although the IC50 value was 43-
times lower for DOTA-PEG-BN(7-14) than for
DOTA-Aoc-BN(7-14), radiolabeling with 64Cu
was performed for further in vitro and in vivo
evaluation.
The internalization assay (Fig. 4) showed a de-
crease in surface bound and internalized radioac-
tivity for 64Cu-DOTA-PEG-BN(7-14) compared to
64Cu-DOTA-Aoc-BN(7-14) that is likely due to the
lower affinity of 64Cu-DOTA-PEG-BN(7-14) for
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Table 1. Biodistribution of 64Cu-DOTA-Aoc BN(7-14) (DOTA-BN) (n5 5) and 64Cu-DOTA-PEG-BN
(7-14) (DOTA-PEG-BN) (n 5 3) in normal, athymic nude mice at 4 hours with and without coinjection of
100 mg of Tyr4-BN blocking agent. The data are expressed as %ID/g with standard deviation in parentheses.
Tisssue DOTA-BN DOTA-BN Block DOTA-PEG-BN DOTA-PEG-BN block
Blood 01.31 (0.38) 01.49 (0.24) 01.30 (0.39) 01.61 (1.12)
Liver 09.92 (1.57) 13.26 (4.32) 10.93 (1.49) 10.69 (3.76)
Sm Int 07.31 (1.11) 07.38 (2.22) 06.50 (1.51) 05.61 (2.51)
Spleen 03.04 (1.60) 02.23 (0.49) 03.79 (1.53) 02.03 (0.86)
Kidney 04.50 (0.59) 04.84 (0.89) 06.26 (1.35) 05.85 (0.80)
Muscle 00.59 (0.03) 00.57 (0.11) 01.25 (0.96) 00.79 (0.50)
Bone 01.67 (0.50) 01.32 (0.27) 02.73 (1.27) 02.00 (1.01)
Panceas 13.69 (1.99) 02.52 (0.52) 10.80 (3.11) 02.42 (1.29)
GRPR. Interestingly, although the affinity of 64Cu-
DOTA-PEG-BN(7-14) for GRPR is low, it still has
significant internalization that is decreased only
2.6-fold relative to 64Cu-DOTA-Aoc-BN(7-14) at
4 hours. This relatively small difference in inter-
nalization may be due to the fact that the assay was
performed with an approximately 10-fold excess of
the radiolabeled ligands over the number of recep-
tors. Studies using various concentrations of the ra-
diolabeled ligands may demonstrate more signifi-
cant differences that correlate with the differences
in IC50. An efflux assay of 64Cu-DOTA-Aoc-
BN(7–14) from PC-3 cells demonstrated a 62% de-
crease in cell-associated activity from 4–18 hours
(data not shown). This is similar to the 72% de-
crease of 64Cu-DOTA-Aoc-BN(7-14) in the pan-
creas from 4–24 hours in Figure 5. This indicates
that 64Cu is not well residualized in GRPR ex-
pressing tissues.
The biodistributions of 64Cu-DOTA-PEG-BN
(7-14) and 64Cu-DOTA-Aoc-BN(7-14) are shown
in Figure 5. We hypothesized that 64Cu-DOTA-
PEG-BN(7–14) would have a longer serum half-
life than 64Cu-DOTA-Aoc-BN(7–14) and would
thus have a higher blood concentration at the
early time points (2 hours and possibly 4 hours).
In addition, we anticipated that this longer serum
half-life would have an effect on the uptake and
clearance in other tissues. However, the differ-
ences in blood clearance were not observed as the
64Cu-DOTA-PEG-BN(7–14) cleared more rapidly
than expected. The reason for the rapid blood
clearance (, 2% ID/g remaining at 2 hours) of
64Cu-DOTA-PEG-BN(7–14) is likely due to the
fact that the size of the PEG linker was not large
enough to avoid rapid renal clearance. DeNardo
et al. evaluated lymphoma specific peptides con-
jugated to PEGs ranging in molecular weight
from 40 kDa to 150 kDa.33 This study showed
that the t1/2 in blood increased from 5.4 hours us-
ing a 40 kDa PEG conjugate to 17.7 hours for the
150 kDa PEG conjugate. This difference is likely
due to the fact that proteins with molecular
weights greater than 69 kDa are generally unable
to filter through the glomerular membrane, while
a protein of 30 kDa has a permeability of 50 per-
cent.34 Thus, future conjugates will consist of
PEG linkers in the 30–80 kDa range. It is antic-
ipated that conjugates within this range of mo-
lecular weights will increase their initial blood
concentration and thus alter their uptake and
clearance in other tissues (including tumors). In
this regard, DeNardo et al. also showed that the
tumor uptake increased as the molecular weight
of the PEG increased.33 We hypothesize that con-
jugates . 80 kDa would have serum half-lives
that are too long to have optimal tissue-to-blood
ratios. These studies will need to be conducted to
determine overall blood clearance and effect on
tissue-to-blood ratios. Of course, as mentioned
above, it may be necessary to incorporate several
BN analogues into the PEG linker to optimize the
affinity of the conjugate for GRPR.
It is interesting that the pancreatic uptake 
of 64Cu-DOTA-Aoc-BN(7–14) is only 1.3-fold
higher than the uptake of 64Cu-DOTA-PEG-
BN(7–14) due the lower affinity of DOTA-PEG-
BN(7–14) for GRPR. It has been shown by oth-
ers and by our group that the mouse pancreas has
a relatively low number of GRPR.30 We found
that the concentration of GRPR on the mouse
pancreas is 27 fmol/mg,30 while Fanger et al. re-
ported a similar level of 75 fmol/mg.35 Therefore,
due to the low specific activity of 64Cu-DOTA-
PEG-BN(7–14) and 64Cu-DOTA-Aoc-BN(7–14) a
relatively large amount of the peptides were in-
jected (41 pmol and 26 pmol, respectively) and no
difference in pancreatic uptake was observed. A
biodistribution study conducted with higher spe-
cific activity 64Cu-DOTA-Aoc-BN(7–14) (108
MBq/nmol; 2924 mCi/nmol), and thus a lower
amount of peptide administered (1.7 pmol vs.26
pmol), showed an increase in pancreatic uptake at
2 hours from 15.2% ID/g to 30.9% ID/g (data not
shown). It is anticipated that a higher specific ac-
tivity for 64Cu-DOTA-PEG-BN(7–14), allowing
the injection of less peptide, would not result in
higher pancreatic uptake due to the low affinity for
GRPR, although this will need to be demonstrated.
CONCLUSION
This study demonstrates that a peptide-PEG con-
jugate can be synthesized and radiolabeled with
64Cu. In particular, DOTA-PEG-BN(7–14) was
synthesized and shown to bind to GRPR-ex-
pressing PC-3 human prostate cancer cells. 64Cu-
DOTA-PEG-BN(7-14) was internalized into PC-
3 cells and demonstrated GRPR-specific uptake
in mouse pancreas after intravenous injection.
Future studies will evaluate the conjugation of
BN analogues with various molecular weight
PEG linkers to determine how the size of the PEG
linker alters the in vivo pharmacokinetics. In ad-
dition, the conjugation of several BN analogues
32
to a PEG linker will be evaluated to determine if
this increases the affinity of the conjugate for
GRPR.
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